» Articles » PMID: 16557868

Agar-Gel Precipitating Antibody in Pseudomonas Aeruginosa Infections

Overview
Journal Infect Immun
Date 1970 Oct 1
PMID 16557868
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The human immune response to Pseudomonas aeruginosa infection was studied by using the double diffusion in agar-gel technique. Antigens from Fisher-Devlin-Gnabasik immunotypes were prepared by both trichloroacetic acid extraction and ultrasonic disruption. Serum from 72 of 168 patients (43%) from whom P. aeruginosa was isolated formed from one to eight precipitin bands. Precipitins were demonstrated in the sera of 60 of 66 (91%) patients recovering from bacteremia and deep infections; however, they were usually absent when Pseudomonas infection was fatal or when there was no clinical evidence of significant infection. Precipitating antibody was detectable at serum dilutions as high as 1:32, and appearance of single bands correlated with hemagglutinating antibody titers of >/=1:128. Antigen from sonically disrupted organisms usually resulted in stronger precipitin bands than trichloroacetic acid extracts, and antigen from the homologous infecting strain occasionally increased test sensitivity. None of 50 normal controls had Pseudomonas precipitins as was the case in patients convalescing from Escherichia coli (15 patients), Klebsiella-Enterobacter-Serratia (18), and Proteus (14) bacteremias. Measurement of agar-gel precipitins was useful and specific in evaluating the circulating antibody response to P. aeruginosa infections.

Citing Articles

Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.

Hatano K, Boisot S, Desjardins D, Wright D, Brisker J, Pier G Infect Immun. 1994; 62(9):3608-16.

PMID: 7520416 PMC: 303009. DOI: 10.1128/iai.62.9.3608-3616.1994.


Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

Pier G J Clin Invest. 1982; 69(2):303-8.

PMID: 6799548 PMC: 370979. DOI: 10.1172/jci110453.


Cross-protection by Pseudomonas aeruginosa polysaccharides.

Pier G Infect Immun. 1982; 38(3):1117-22.

PMID: 6185423 PMC: 347865. DOI: 10.1128/iai.38.3.1117-1122.1982.


High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.

Pier G, Sidberry H, Sadoff J Infect Immun. 1981; 34(2):461-8.

PMID: 6171520 PMC: 350889. DOI: 10.1128/iai.34.2.461-468.1981.


Precipitating antibody against core glycolipid of Enterobacteriaceae.

Young L, STEVENS P Experientia. 1974; 30(2):192-3.

PMID: 4205369 DOI: 10.1007/BF01927729.


References
1.
Verder E, Evans J . A proposed antigenic schema for the identification of strains of Pseudomonas aeruginosa. J Infect Dis. 1961; 109:183-93. DOI: 10.1093/infdis/109.2.183. View

2.
FINLAND M, JONES Jr W, BARNES M . Occurrence of serious bacterial infections since introduction of antibacterial agents. J Am Med Assoc. 1959; 170:2188-97. DOI: 10.1001/jama.1959.63010180008012. View

3.
Feingold D, OSKI F . PSEUDOMONAS INFECTION. TREATMENT WITH IMMUNE PLASMA. Arch Intern Med. 1965; 116:326-8. DOI: 10.1001/archinte.1965.03870030006002. View

4.
Gaines S, Landy M . Prevalence of antibody to Pseudomonas in normal human sera. J Bacteriol. 1955; 69(6):628-33. PMC: 357601. DOI: 10.1128/jb.69.6.628-633.1955. View

5.
RABIN E, GRABER C, VOGEL Jr E, Finkelstein R, TUMBUSCH W . Fatal pseudomonas infection in burned patients. A clinical, bacteriologic and anatomic study. N Engl J Med. 1961; 265:1225-31. DOI: 10.1056/NEJM196112212652501. View